Abstract
To investigate the frequency of hepatitis B virus (HBV)-related events after allogeneic HCT in a moderate endemic area for HBV infection. The data of 197 patients who underwent allogeneic hematopoetic stem cell transplatation (HCT) from September 2003 through December 2010 were reviewed retrospectively with respect to HBV-related events. Resolved HBV infection was described as negative HBsAg, positive HBcAb, and positive HBsAb. Latent HBV infection was defined in patients with HBcAb positivity in the abscence of HBV DNA and HBsAb. Hepatitis B naive patients are defined as the patiens with no serological or molecular marker related to HBV. Seropositive patients were the patients with positive HBsAg and HBV-DNA. Median age was 28 (range, 15–64) years, with 128 male and 69 female patients. Median follow-up of the cohort was 8 (range, 0.5–78) months. We detected HBV-related events in 7 (3.6 %) recipients after allogeneic HCT. Five (71.4 %) of these events were HBV reactivation, while two cases (28.6 %) had acute hepatitis B infection. Four of the five reactivations were in the seropositive group (80 %), while one ocurred in a patient with resolved hepatitis. Two patients who developed acute hepatitis B were HBV naive and previously immunized patients, respectively. Hepatitis B virus reactivation remains a problem in seropositive patients and might require more effective treatment strategies.
Similar content being viewed by others
References
Dienstag JL, Hepatitis B (2008) Virus infection. N Engl J Med 359:1486–1500
Hu KQ (2002) Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 9:243–257
Emektaş G, Çavuşlu S, Öncül O, Artuk C, Aksoy A (2006) Trends in hepatitis B and hepatitis C virus among blood donors over 16 years in turkey. Eur J Epidemiol 21:299–305
Liang R (2009) How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 113:3147–3153
Hammond SP, Borchelt AM, Ukomadu C, Ho VT, Baden LR, Marty FM (2009) Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15:1049–1059
Knoll A, Boehm S, Hahn J, Holler E, Jilg W (2004) Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 33:925–929
Ramos CA, Saliba RM, de Pádua L, Silva OK, Shpall EJ, Giralt S, Patah PA, Hosing CM, Popat UR, Rondon G, Nieto Y, Champlin RE, de Lima M (2010) Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 16:686–694
McDonald GB (2010) Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology 51:1450–1460
Lalazar G, Rund D, Shouval D (2007) Screening, prevention and treatment of viral hepatitis B reactivationin patients with haematological malignancies. Br J Haematol 136:699–712
Çeneli O, Ozkurt ZN, Acar K, Rota S, Aki SZ, Yeğin ZA, Yağci M, Ozenirler S, Sucak GT (2010) Hepatitis related events in autologous hematopoietic stem cell transplantation recipients. World J Gastroenterol 16:1765–1771
Knoll S, Boehm J, Hahn EH, Jilg W (2007) Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor. J Viral Hepat 14:478–483
Dhédin N, Douvin C, Kuentz M, Saint Marc MF, Reman O, Rieux C, Bernaudin F, Norol F, Cordonnier C, Bobin D, Metreau JM, Vernant JP (1998) Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 66:616–619
Locasciulli A, Bruno B, Alessandrino EP, Meloni G, Arcese W, Bandini G, Cassibba V, Rotoli B, Morra E, Majolino I, Alberti A, Bacigalupo A (2003) Viral infections hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant 31:295–300
Lau GK, Liang R, Chiu EK, Lee CK, Lam SK (1997) Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study. Bone Marrow Transplant 19:795–799
Hui CK, Lie A, Au WY, Leung YH, Ma SY, Cheung WW, Zhang HY, Chim CS, Kwong YL, Liang R, Lau GK (2005) A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation. Blood 106:464–469
Hsiao LT, Chiou TJ, Gau JP, Liu JH, Tzeng CH, Chen PM (2009) Hepatitis B infection in haematopoietic stem cell transplantation: still unresolved. Hong Kong Med J 15(Suppl 3):42–44
Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R (2008) Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat 15:89–102
Yeo W, Johnson PJ (2006) Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43:209–220
Lau GK, He ML, Fong DY, Bartholomeusz A, Au WY, Lie AK, Locarnini S, Liang R (2002) Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 36:702–709
Sugauchi F, Tanaka Y, Kusumoto S, Matsuura K, Sugiyama M, Kurbanov F, Ueda R, Mizokami M (2011) Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy. J Med Virol 83:412–418
Lee YC, Young KC, Su WC, Tsao CJ, Chen TY (2004) Emergence of YMDD mutant Hepatitis B virus after allogeneic stem cell transplantation from a HBsAG-positive donor during lamivudine prophylaxis. Haematologica 89:30–31
Fouillard L, Serfaty L, Gozlan J (2006) Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 37:625–626
Seth P, Alrajhi AA, Kagevi I, Chaudhary MA, Colcol E, Sahovic E, Aljurf M, Gyger M (2002) Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transplant 30:189–194
Matsue K, Aoki T, Odawara J, Fujiwara H, Iwama K, Kimura S, Yamakura M, Takeuch M (2009) High risk of hepatitis B-virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody-positive patients. Eur J Haematol 83(4):357–364
Alexopoulou A, Theodorou M, Dourakis SP, Karayiannis P, Sagkana E, Papanikolopoulos K, Archimandritis AJ (2006) Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations. J Viral Hepat 13(9):591–596
Picardi M, De Rosa G, Selleri C, Pane F, Rotoli B, Muretto P (2006) Clinical relevance of intrahepatic hepatitis B virus DNA in HBsAg-negative HBcAb-positive patients undergoing hematopoietic stem cell transplantation for hematological malignancies. Transplantation 82:141–142
Conflict of interest
All authors declare that they do not have conflict of interest
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Çakar, M.K., Suyanı, E., Sucak, G.T. et al. HBV-related events after allogeneic hematopoetic stem cell transplantatıon in a center from Turkey. Ann Hematol 92, 395–402 (2013). https://doi.org/10.1007/s00277-012-1620-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-012-1620-1